Drug Profile


Alternative Names: BCX 2600; Diacomit; ME-2080

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biocodex
  • Developer Biocodex; Meiji Seika Pharma
  • Class Antiepileptic drugs; Dioxolanes; Neuroprotectants
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myoclonic epilepsies

Most Recent Events

  • 17 Aug 2017 Biocodex completes a phase II trial for Myoclonic epilepsies in France
  • 31 Jan 2012 Preregistration for Myoclonic epilepsies in Japan (PO, capsule)
  • 31 Jan 2012 Preregistration for Myoclonic epilepsies in Japan (PO, suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top